MedTrace Logo

Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative Therapy

NCT05112627 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2024-08-09

No results posted yet for this study

Summary

This early phase I trial evaluates blood samples to see if patients undergoing standard of care treatment with either stereotactic body radiation therapy or percutaneous ablation (using radio waves to create heat to destroy the tumor), have an increase in serum immune markers in kidney cancer. Information gained from this study may help doctors make treatment decisions for patients with kidney cancer.

Conditions

  • Metastatic Renal Cell Carcinoma
  • Stage IV Renal Cell Cancer AJCC v8

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood collection

Sponsors & Collaborators

Principal Investigators

  • Bradley J. Stish, M.D. · Mayo Clinic in Rochester

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-24
Primary Completion
2024-05-15
Completion
2024-05-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05112627 on ClinicalTrials.gov